Editor's Choice – Vascular Access: 2018 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS)

Schmidli, Jürg; Widmer, Matthias; Basile, Carlo; Donato, Gianmarco de; Gallieni, Maurizio; Gibbons, C.P.; Haage, Patrick; Hamilton, Geoff W.; Hedin, Ulf; Kamper, Lars; Lazarides, Miltos K.; Lindsey, Ben; Mestres, Gaspar; Pegoraro, Marisa; Roy, Joy; Setacci, Carlo; Shemesh, David; Tordoir, Jan H.M.; Loon, Magda van; Committee, ESVS Guidelines; Kolh, Philippe; Borst, Gert J. de; Chakfé, Nabil; Debus, Sebastian; Hinchliffe, R.J.; Kakkos, Stavros K.; Končar, Igor; Lindholt, Jes Sanddal; Naylor, Ross; Céniga, Melina Vega de; Vermassen, Frank; Verzini, Fabio; Reviewers, ESVS Guidelines; Mohaupt, Markus; Ricco, Jean‐Baptiste; Roca-Tey, Ramón

doi:10.1016/j.ejvs.2018.02.001

Cited by 543 publications

(611 citation statements)

References 558 publications

Supporting

Mentioning

536

Contrasting

Unclassified

Order By: Relevance

“…(iv) Upper limb ALI is covered in section 7 (Diagnosis and Treatment of Upper Limb Acute Ischaemia), but treatment of patients who develop this condition during renal replacement therapy is covered by the Vascular Access 2018 Clinical Practice Guidelines of the ESVS. 8 (v) Ischaemia may also develop secondary to deep venous thrombosis, and secondary low arterial blood flow, but this condition (phlegmasia cerulea dolens) is covered by the 2015 ESVS Venous Guidelines. 9 (vi) Blue toe syndrome, when emboli lodge in the arteries of the toes (or fingers; often referred to as endarteries, as they lack collaterals) is often associated with great pain but is not covered by these guidelines, as the condition does not result in limb ischaemia.…”

Section: Classes Of Recommendation Definitionmentioning

confidence: 99%

Editor's Choice – European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia

Björck

Earnshaw

Acosta

et al. 2020

European Journal of Vascular and Endovascular Surgery

Self Cite

287

197

View full text Add to dashboard Cite

Section: Classes Of Recommendation Definitionmentioning

confidence: 99%

Editor's Choice – European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia

Björck

Earnshaw

Acosta

et al. 2020

European Journal of Vascular and Endovascular Surgery

Self Cite

287

197

View full text Add to dashboard Cite

“…Nonetheless, systemic reviews or meta-analysis showed controversial or no beneficial effects [34,35]. Currently, no pharmacotherapy has been recommended by the guidelines to promote AV fistula maturation [36,37]. Our study demonstrated that adsorbents of uremic toxins administered in the perioperative period could attenuate neointima formation and improve patency of AV fistula.…”

Section: Discussionmentioning

confidence: 69%

Oral Charcoal Adsorbents Attenuate Neointima Formation of Arteriovenous Fistulas

Shih

Wang

et al. 2020

Toxins

View full text Add to dashboard Cite

Chronic kidney disease (CKD) accelerates the development of neointima formation at the anastomosis site of arteriovenous (AV) fistulas. Accumulation of certain uremic toxins has a deleterious effect on the cardiovascular system. The oral charcoal adsorbent, AST-120, reduces circulating and tissue uremic toxins, but its effect on neointima formation at an AV fistula is unknown. To understand the effect of CKD and AST-120 on neointima formation, we created AV fistulas (common carotid artery to the external jugular vein in an end-to-side anastomosis) in mice with and without CKD. AST-120 was administered in chow before and after AV fistula creation. Administration of AST-120 significantly decreased serum indoxyl sulfate levels in CKD mice. CKD mice had a larger neointima area than non-CKD mice, and administration of AST-120 in CKD mice attenuated neointima formation. Both smooth muscle cell and fibrin components were increased in CKD mice, and AST-120 decreased both. RNA expression of MMP-2, MMP-9, TNFα, and TGFβ was increased in neointima tissue of CKD mice, and AST-120 administration neutralized the expression. Our results provided in vivo evidence to support the role of uremic toxin-binding therapy on the prevention of neointima formation. Peri-operative AST-120 administration deserves further investigation as a potential therapy to improve AV fistula patency.

show abstract

“…A least inner vessel size for cephalic vein and radial artery of two millimeters with a proximal tourniquet is well-thought-out to remain sufficient for effective AVF formation and to become mature. For brachiobasilic arteriovenous fistula and brachiocephalic arteriovenous fistula a least artery and vein size of three millimeters is adequate (Schmidli et al, 2018).…”

Section: Autogenous Arteriovenous Accessmentioning

confidence: 99%

Vascular Access for Hemodialysis in Pediatric Age

Eissa¹,

Mowafy²,

Regal³

et al. 2020

IJAR

View full text Add to dashboard Cite

Editor's Choice – Vascular Access: 2018 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS)

Cited by 543 publications

References 558 publications

Editor's Choice – European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia

Editor's Choice – European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia

Oral Charcoal Adsorbents Attenuate Neointima Formation of Arteriovenous Fistulas

Vascular Access for Hemodialysis in Pediatric Age

Contact Info

Product

Resources

About